120 related articles for article (PubMed ID: 19837750)
1. Chemotherapy response monitoring of colorectal liver metastases by dynamic Gd-DTPA-enhanced MRI perfusion parameters and 18F-FDG PET metabolic rate.
Vriens D; van Laarhoven HW; van Asten JJ; Krabbe PF; Visser EP; Heerschap A; Punt CJ; de Geus-Oei LF; Oyen WJ
J Nucl Med; 2009 Nov; 50(11):1777-84. PubMed ID: 19837750
[TBL] [Abstract][Full Text] [Related]
2. Prediction of chemotherapeutic response of colorectal liver metastases with dynamic gadolinium-DTPA-enhanced MRI and localized 19F MRS pharmacokinetic studies of 5-fluorouracil.
van Laarhoven HW; Klomp DW; Rijpkema M; Kamm YL; Wagener DJ; Barentsz JO; Punt CJ; Heerschap A
NMR Biomed; 2007 Apr; 20(2):128-40. PubMed ID: 17006886
[TBL] [Abstract][Full Text] [Related]
3. Gadopentetate dimeglumine and FDG uptake in liver metastases of colorectal carcinoma as determined with MR imaging and PET.
van Laarhoven HW; de Geus-Oei LF; Wiering B; Lok J; Rijpkema M; Kaanders JH; Krabbe PF; Ruers T; Punt CJ; van der Kogel AJ; Oyen WJ; Heerschap A
Radiology; 2005 Oct; 237(1):181-8. PubMed ID: 16183932
[TBL] [Abstract][Full Text] [Related]
4. Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET.
Jansen JF; Schöder H; Lee NY; Stambuk HE; Wang Y; Fury MG; Patel SG; Pfister DG; Shah JP; Koutcher JA; Shukla-Dave A
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):299-307. PubMed ID: 21236594
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis.
Hirashima Y; Yamada Y; Tateishi U; Kato K; Miyake M; Horita Y; Akiyoshi K; Takashima A; Okita N; Takahari D; Nakajima T; Hamaguchi T; Shimada Y; Shirao K
Int J Cancer; 2012 May; 130(10):2359-65. PubMed ID: 21780098
[TBL] [Abstract][Full Text] [Related]
6. Diffusion-Related MRI Parameters for Assessing Early Treatment Response of Liver Metastases to Cytotoxic Therapy in Colorectal Cancer.
Kim JH; Joo I; Kim TY; Han SW; Kim YJ; Lee JM; Han JK
AJR Am J Roentgenol; 2016 Sep; 207(3):W26-32. PubMed ID: 27303858
[TBL] [Abstract][Full Text] [Related]
7. Vascular and metabolic response to bevacizumab-containing regimens in two patients with colorectal liver metastases measured by dynamic contrast-enhanced MRI and dynamic 18F-FDG-PET.
Vriens D; de Geus-Oei LF; Heerschap A; van Laarhoven HW; Oyen WJ
Clin Colorectal Cancer; 2011 Mar; 10(1):E1-5. PubMed ID: 21609927
[TBL] [Abstract][Full Text] [Related]
8. Value of retrospective fusion of PET and MR images in detection of hepatic metastases: comparison with 18F-FDG PET/CT and Gd-EOB-DTPA-enhanced MRI.
Donati OF; Hany TF; Reiner CS; von Schulthess GK; Marincek B; Seifert B; Weishaupt D
J Nucl Med; 2010 May; 51(5):692-9. PubMed ID: 20395324
[TBL] [Abstract][Full Text] [Related]
9. Detection and Viability of Colorectal Liver Metastases After Neoadjuvant Chemotherapy: A Multiparametric PET/CT-MRI Study.
Dunet V; Halkic N; Prior JO; Anaye A; Meuli RA; Sempoux C; Denys A; Schmidt S
Clin Nucl Med; 2017 Apr; 42(4):258-263. PubMed ID: 28166142
[TBL] [Abstract][Full Text] [Related]
10. Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer.
Partridge SC; Vanantwerp RK; Doot RK; Chai X; Kurland BF; Eby PR; Specht JM; Dunnwald LK; Schubert EK; Lehman CD; Mankoff DA
J Magn Reson Imaging; 2010 Nov; 32(5):1124-31. PubMed ID: 21031518
[TBL] [Abstract][Full Text] [Related]
11. Correlation Between F-18 Fluorodeoxyglucose Positron Emission Tomography Metabolic Parameters and Dynamic Contrast-Enhanced MRI-Derived Perfusion Data in Patients with Invasive Ductal Breast Carcinoma.
Kim TH; Yoon JK; Kang DK; Lee SJ; Jung YS; Yim H; An YS
Ann Surg Oncol; 2015 Nov; 22(12):3866-72. PubMed ID: 25805237
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic cancer: utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy.
Akisik MF; Sandrasegaran K; Bu G; Lin C; Hutchins GD; Chiorean EG
Radiology; 2010 Aug; 256(2):441-9. PubMed ID: 20515976
[TBL] [Abstract][Full Text] [Related]
13. Method for quantitation of dynamic MRI contrast agent uptake in colorectal liver metastases.
van Laarhoven HW; Rijpkema M; Punt CJ; Ruers TJ; Hendriks JC; Barentsz JO; Heerschap A
J Magn Reson Imaging; 2003 Sep; 18(3):315-20. PubMed ID: 12938126
[TBL] [Abstract][Full Text] [Related]
14. Multimodality imaging to predict response to systemic treatment in patients with advanced colorectal cancer.
Heijmen L; ter Voert EE; Oyen WJ; Punt CJ; van Spronsen DJ; Heerschap A; de Geus-Oei LF; van Laarhoven HW
PLoS One; 2015; 10(4):e0120823. PubMed ID: 25831053
[TBL] [Abstract][Full Text] [Related]
15. Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab.
Lastoria S; Piccirillo MC; Caracò C; Nasti G; Aloj L; Arrichiello C; de Lutio di Castelguidone E; Tatangelo F; Ottaiano A; Iaffaioli RV; Izzo F; Romano G; Giordano P; Signoriello S; Gallo C; Perrone F
J Nucl Med; 2013 Dec; 54(12):2062-9. PubMed ID: 24136935
[TBL] [Abstract][Full Text] [Related]
16. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI.
Wong CY; Salem R; Raman S; Gates VL; Dworkin HJ
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):815-20. PubMed ID: 12029557
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil.
Findlay M; Young H; Cunningham D; Iveson A; Cronin B; Hickish T; Pratt B; Husband J; Flower M; Ott R
J Clin Oncol; 1996 Mar; 14(3):700-8. PubMed ID: 8622014
[TBL] [Abstract][Full Text] [Related]
18. Changes in hepatic perfusion assessed by dynamic contrast enhanced MRI, associated with morphologic evaluation, in patients with liver metastases from colorectal cancer treated with first-line chemotherapy.
Tampellini M; Gned D; Baratelli C; Brizzi MP; Ottone A; Alabiso I; Bertaggia C; Di Maio M; Scagliotti GV; Veltri A
Radiol Med; 2016 Dec; 121(12):950-957. PubMed ID: 27601143
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer.
de Geus-Oei LF; van der Heijden HF; Visser EP; Hermsen R; van Hoorn BA; Timmer-Bonte JN; Willemsen AT; Pruim J; Corstens FH; Krabbe PF; Oyen WJ
J Nucl Med; 2007 Oct; 48(10):1592-8. PubMed ID: 17873138
[TBL] [Abstract][Full Text] [Related]
20. Can combined 18F-FDG-PET and dynamic contrast-enhanced MRI predict behavior of desmoid tumors in patients with familial adenomatous polyposis?
Bhandari S; Taylor NJ; Sinha A; Sonoda L; Sanghera B; Wong WL; Goh V; Clark SK
Dis Colon Rectum; 2012 Oct; 55(10):1032-7. PubMed ID: 22965401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
